These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 2879296)

  • 1. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
    Meya U; Renfordt E
    Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 3. Initial improvement as a criterion for drug choice in acute schizophrenia.
    Klimke A; Klieser E; Lehmann E; Miele L
    Pharmacopsychiatry; 1993 Jan; 26(1):25-9. PubMed ID: 8104348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
    Schmidt LG; Siemetzki H
    Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
    [No Abstract]   [Full Text] [Related]  

  • 5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
    Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
    Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial improvement as predictor of outcome of neuroleptic treatment.
    Nedopil N; Rüther E
    Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.
    Rein W; Schied HW; Breyer-Pfaff U; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):147-51. PubMed ID: 6140693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
    Asato N; Hirayasu Y; Hiramatsu K; Ohta H
    Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness].
    Wetzel H; von Bardeleben U; Holsboer F; Benkert O
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies of the effects of perazine, fluphenazine, trifluoperazine, chlorpromazine and haloperidol on primary and deficit symptoms of paranoid schizophrenia].
    Termińska K; Mrowiec W
    Psychiatr Pol; 1989; 23(1):24-30. PubMed ID: 2573098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
    Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
    Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
    Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
    [No Abstract]   [Full Text] [Related]  

  • 16. Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine.
    Litman RE; Hommer DW; Clem T; Rapaport MH; Pato CN; Pickar D
    Psychopharmacol Bull; 1989; 25(3):473-8. PubMed ID: 2576322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
    Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
    Dieterle DM; Müller-Spahn F; Ackenheil M
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.